Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis

Sep 6, 2022 Press Releases

PDF Version Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition element This novel system may serve as an adjunct to anti-amyloid monoclonal antibodies for the enhanced clearance of tissue amyloid SAN...

Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis

Sep 6, 2022 Press Releases

PDF Version AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleen AT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrils AT-02 binds potently to multiple types of amyloid including ATTR, AL, and ALECT2 SAN FRANCISCO, Calif....

Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Aug 22, 2022 Press Releases

PDF Version SAN FRANCISCO, Calif. – August 22, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that new data across the Company’s...

Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis

Aug 8, 2022 Press Releases

PDF Version SAN FRANCISCO, Calif. – August 8, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug...

Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 14, 2022 Press Releases

PDF Version AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis AT-01 visualizes and quantifies organ-specific changes in amyloid load over time AT-01 detected patients with diverse types of systemic amyloidosis, by...